JohnPClancyMD

Pediatric Pulmonology • Cincinnati, OH

Professor, Pediatrics, University of Cincinnati College of Medicine

Join to view full profile

Dr. Clancy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Clancy's full profile

Already have an account?

Office
3333 Burnet Ave., Ml 2021
Cincinnati Children's Hospital
Cincinnati, OH 45229
Phone+1 513-636-6771

Fax+1 513-636-4615

Education & Training

University of Alabama Medical CenterFellowship, Pediatric Pulmonology, 1993 - 1996
University of Virginia Medical CenterResidency, Pediatrics, 1990 - 1993
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1990

Certifications & Licensure

OH State Medical License 2011 - 2021
AL State Medical License 1993 - 2011

Clinical Trials

PTC124 for Cystic Fibrosis Start of enrollment: 2005 Sep 01
Completed
Phase 2
Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects Start of enrollment: 2009 Oct 01
Completed
Sildenafil Trial in Children and Young Adults With CF Start of enrollment: 2012 Aug 01
Withdrawn
Phase 1, Phase 2
Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Withdrawn
Phase 3
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection Start of enrollment: 2012 Oct 05
Completed
Phase 3
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) Start of enrollment: 2011 Apr 01
Terminated
Phase 2
G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2) Start of enrollment: 2014 Jan 01
Completed
Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF Start of enrollment: 2013 Feb 01
Completed
Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Start of enrollment: 2013 Jun 01
Completed
Phase 2
Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF) Start of enrollment: 2013 Apr 01
Completed
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis Start of enrollment: 2014 Jun 01
Completed
Phase 3
Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation Start of enrollment: 2015 Sep 01
Completed
Phase 1
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation Start of enrollment: 2015 Nov 01
Completed
Phase 2
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor Start of enrollment: 2016 Apr 01
Unknown status
Phase 2
Join now to see all

Publications & Presentations

PubMed

Elexacaftor/Tezacaftor/Ivacaftor Markedly Reducesin Cystic Fibrosis.
Sarah J Morgan, David P Nichols, Windy Ni, Gina Hong, Stephen J Salipante
American Journal of Respiratory and Critical Care Medicine. 2024-11-01
2 citations
Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis.
Theodore G Liou, Natalia Argel, Fadi Asfour, Perry S Brown, Barbara A Chatfield
Iscience. 2024-03-15
4 citations
Built environment factors predictive of early rapid lung function decline in cystic fibrosis.
Emrah Gecili, Cole Brokamp, Erika Rasnick, Pedro M Afonso, Eleni-Rosalina Andrinopoulou
Pediatric Pulmonology. 2023-05-01

Grant Support

Clinical CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2011
Phase 3 Study Evaluating Aztreonam Lysiante For Inhalation In Cystic FibrosisNational Center For Research Resources2007
Eur-1009-MNational Center For Research Resources2007
Eur-1008-MNational Center For Research Resources2007
PTCNational Center For Research Resources2006–2007
Long-Term Continuation Study Of Patients With Infantile-Onset Pompe DiseaseNational Center For Research Resources2006–2007
Myozyme In Patients With Infantile-Onset Pompe DiseaseNational Center For Research Resources2005–2007
Treatment In Patients <6 Months Old With Infantile-Onset Pompe Disease (1602)National Center For Research Resources2006
Induced Sputum As A Tool To Evaluate Anti-Inflammatory Agents In CF PatientsNational Center For Research Resources2005–2006
Pompe 1602National Center For Research Resources2005
Oral Theraclec Tm-Total In CF Subjects With Exocrine Pancreatic InsufficiencyNational Center For Research Resources2005
A Multicenter, Phase II Study Of Aerosolized Tgaavcf For The Treatment Of CFNational Center For Research Resources2005
PH. II Study Of Aerosolized Tgaavcf For Treatment Of CFNational Center For Research Resources2004
Open-Label Safety And Tolerability Study Of TheraclecNational Center For Research Resources2004
Nebulized Aztreonam In CF PatientsNational Center For Research Resources2004
Regulation Of CFTR By Adenosine, A2 Receptors, And PLA2National Heart, Lung, And Blood Institute2001–2004
Pilot--Pseudovirion Vectors For CFTR DeliveryNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002

JohnPClancyMD

Dr. Clancy is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.